Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)
Authors not listed
Allergan · 2015
Abstract
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Anonymous. (2015). Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study). <em>Allergan</em>. https://clinicaltrials.gov/study/NCT02462486
Vancouver
Anonymous. Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study). Allergan. 2015.
BibTeX
@misc{anon2015Safety,
title = {Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)},
author = {Anonymous},
journal = {Allergan},
year = {2015},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.